After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

The global organ on a chip market was valued at US$ 157.06 million in 2024 and is expected to reach US$ 2,238.28 million by ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

In addition, Nurix anticipates moving into autoimmune and inflammatory ... obligations in the current period related to the collaboration with Pfizer. During the three months ended February ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

“Sanofi’s dedication to this program expands our mutual drug discovery pipeline in autoimmune ... under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc ...

Market OverviewThe global Vaccines Market has evolved significantly in recent years, driven by advancements in biotechnology, ...

Learn more about whether Alvotech or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...